Health Catalyst, Inc.

Health Catalyst, Inc. Q4 FY2019 earnings

HCAT

Quarter ended Dec 2019.

← Q3 FY2019Q1 FY2020 →
Revenue
$43.5M
Operating margin
-31.4%
Net income
-$14.3M

Summary

Health Catalyst closed fiscal 2019 with fourth-quarter revenue of $43.50 million, up 20.6% from the prior-year quarter, and full-year revenue of $154.94 million, up 37.6%. Profitability is still the weak spot. The fourth-quarter operating loss widened 5.7% to $13.67 million, and the net loss widened 5.1% to $14.27 million. For the full year the losses narrowed, with an operating loss of $54.86 million, an improvement of 8.7%, and a net loss of $60.10 million, an improvement of 3.0%. Diluted loss per share for the year was $12.86. Operating margin came in at negative 31.4% for the quarter, up 4.4 percentage points from negative 35.8%, and negative 35.4% for the year, up 18.0 points from negative 53.4%.

Growth stayed balanced across the two revenue lines. Technology revenue was 54% of full-year revenue and professional services 46%, a mix the MD&A attributes to new DOS Subscription Customers and to existing customers paying higher technology access fees through contractual, annual escalators. On a non-GAAP basis, total adjusted gross margin was 51% in the quarter against 49% a year earlier, and 52% for the year against 48%. Adjusted EBITDA was negative $6.5 million for the quarter, narrower than the negative $9.4 million reported a year earlier, and negative $27.4 million for the full year, narrower than negative $38.1 million. Stock-based compensation and the February 2019 debt refinancing charge keep the gap between adjusted and GAAP results wide.

Commercial traction held. DOS Subscription Customers totaled 65 at December 31, 2019, against 50 a year earlier and 34 at the end of 2017. The dollar-based retention rate was 109% for 2019, after 107% in 2018. Deferred revenue was $32.10 million, flat versus the prior-year quarter, and remaining performance obligations were $54.60 million. Cash generation remains negative. Net cash used in operating activities was $32.18 million for the full year, up 20.1% from the prior year, and $13.06 million in the quarter, down 0.6%. Capital expenditures, reported as purchases of property and equipment, were $0.74 million in the quarter, down 51.1%, and $2.40 million for the year, up 5.5%. The MD&A ties the fourth-quarter lift in professional services revenue to Medicity, now called Health Catalyst Interoperability.

Guidance points to continued losses. For the first quarter of 2020, management guided to adjusted EBITDA of negative $8.5 million to negative $6.5 million. For the full year 2020, the range is negative $23.5 million to negative $20.5 million. The company also provides total revenue guidance for the next quarter and for the full year, but it does not reconcile adjusted EBITDA guidance to net loss, its most directly comparable GAAP measure, and it gives no net loss guidance because items such as stock-based compensation fall outside its control.

The risk list is short but pointed: changes in laws and regulations affecting the business model, shifts in market or industry conditions and customer receptivity, litigation or a security incident, the loss of key customers or partners, and difficulty recruiting and retaining team members. Two company-specific issues stand out. Medicity customers are expected to produce flat to declining revenue and historically retain at a lower rate than DOS Subscription Customers, so cross-selling must offset that drag. Moving on-premise and private data center customers to Microsoft Azure raises the cost of technology revenue per customer and works against adjusted technology gross margin. Long procurement cycles at large health systems may also slow new customer additions. Federal and state net operating loss carryforwards begin to expire in 2032 and 2024 and could be limited by ownership changes under Sections 382 and 383. The balance sheet carries $50.0 million drawn on the OrbiMed facility at a 10.0% rate.

Forecast

Management guidance
ReportedGuidance

Guided revenue, Q1 FY2020$42.0M – $45.0M
Midpoint$43.5M
Growth vs Q4 FY2019-0.0%
Q1 2020
Adjusted EBITDA$(8.5) million - $(6.5) million
Full Year 2020
Total revenue$185.0 million - $188.0 million
Adjusted EBITDA$(23.5) million - $(20.5) million

Reported figures

GAAP, from SEC filings
MetricQ4 FY2019Q3 FY2019QoQQ4 FY2018YoY
Revenue$43.5M$39.4M+10.3%——
Research & development$13.0M$13.5M-3.2%——
Sales & marketing$11.7M$14.7M-20.5%——
General & administrative$8.4M$11.0M-23.9%——
Total operating expenses$35.5M$41.5M-14.5%——
Operating income (loss)-$13.7M-$20.7M+34.1%——
Operating margin-31.4%-52.6%+21.2 pp——
Net income (loss)-$14.3M-$21.4M+33.4%——
Net margin-32.8%-54.3%+21.5 pp——

Risks

HIGHData Access

Our data platform depends on sourcing data from third-party clinical, financial, and operational systems; information blocking practices and uncertainty over the 21st Century Cures Act Proposed Rule could limit data interfaces and impair analytics delivery.

HIGHCloud Migration

We are transitioning customers from our private data center and on-premise deployments to Microsoft Azure, which MD&A says is more costly per customer and will create a headwind against Adjusted Technology Gross Margin; the transition is expected to be substantially complete by the end of 2020.

HIGHAcquisition Integration

Medicity customers historically generated a lower Dollar-based Retention Rate than DOS Subscription Customers, and MD&A expects flat to declining revenue from Medicity customers in the foreseeable future as the cross-sell and technology integration efforts remain in early phases.

HIGHCompetition

We compete with EHR companies such as Epic and Cerner and larger analytics vendors such as Optum Analytics and IBM; increasing EHR market share in data analytics may cause existing customers to terminate contracts or demand less favorable terms.

HIGHClinical Liability

If our analytics are associated with faulty clinical decisions or treatment, customers, clinicians, or patients could assert product liability or medical malpractice claims, and insurance may not cover all damages.

MEDIUMSales Cycle

New customer sales cycles average 11 months and have exceeded 24 months, and MD&A notes large healthcare provider buying patterns can cause quarterly variability in contracting activity and slow new customer additions.

MEDIUMConcentration Risk

Our three largest customers represented 11.8% of revenue in 2019, compared with 17.5% in 2018, and the sudden loss or renegotiation of any large customer contract could adversely affect results.

MEDIUMPricing

In Q4 2018 we began introducing new pricing for new customers, but MD&A says there were no material revenue increases from those pricing adjustments in 2019 and 2018 and that limited experience pricing newer applications may lead to underpricing or overpricing.

MEDIUMRevenue Mix

Technology and professional services have materially different gross margin profiles, with professional services representing 46% of FY2019 total revenue and carrying lower gross margin, so shifts in mix can pressure Total Adjusted Gross Margin.

MEDIUMProfitability

Net loss narrowed to $60.1 million in FY2019 from $62.0 million in FY2018, but we continue to incur significant losses and may need additional capital to fund operations.

DOS Subscription Customers
65
Dollar-based Retention Rate
109%

DOS Subscription Customers

3 quarters
65
Q4 FY2019

Summary, forecast, risks and KPIs are extracted from Health Catalyst, Inc.'s SEC filings for Q4 FY2019 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 21, 2026.